• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Can high-calorie refeeding process lead to better anorexia outcomes?

Article

When treating patients with anorexia nervosa and malnourishment, the current standard of care involves starting with low calories and then advancing with caution. A new investigation examines whether a higher calorie refeeding protocol could be more beneficial to patients with no increase in adverse events.

When a patient is in the early days of being treated for the malnourishment associated with anorexia nervosa, the current standard of care includes administering low calorie refeeding and being cautious in increasing the number of calories. A new investigation in JAMA Pediatrics looks at whether utilizing a higher-calorie regimen could perform just as well or even better.1 It was the first randomized clinical trial in the United States to compare refeeding protocols.

The investigators ran a multicenter randomized clinical trial that had prospective follow-up. It was conducted at large tertiary care hospitals, using 2 inpatient eating disorder programs . The participants were hospitalized for anorexia nervosa or atypical anorexia nervosa. They had 60% or more of median body mass index. The investigators were comparing lower-calorie refeeding, which started at 1400 kcal and increased by 200 kcal every other day, with higher-calorie refeeding, which started at 2000 kcal and increasing by 200 kcal per day.

There were 120 participants enrolled in the study, but 9 withdrew before treatment, leaving 111 participants who were aged 12 to 24 years. The researchers found that higher-calorie refeeding reestablished medical stability significantly earlier than the lower-calorie refeeding protocol (hazard ratio, 1.67 [95% CI, 1.10-2.53]; P = .01). However, electrolyte abnormalities as well as other adverse events were not different between the groups. Patients who were given the higher-calorie refeeding regimen had a hospital stay that was on average 4.0 days shorter (95% CI, −6.1 to −1.9 days). The shorter stay led to an average savings of $19,056 in hospital charges per participant.

The researchers concluded that using a more rigorous refeeding program in malnourished patients with both anorexia nervosa and atypical anorexia nervosa led to nutritional gains. Most importantly, these gains did not come with an increased number of safety events during the patient’s hospitalization. Plus, patients who received the higher calorie refeeding program were able to leave the hospital earlier than those who received the standard of care program, meaning significant medical savings.

Reference

1. Garber A, Cheng J, Accurso E, et al. Short-term outcomes of the study of refeeding to optimize inpatient gains for patients with anorexia nervosa. JAMA Pediatr. October 19, 2020. Epub ahead of print. doi:10.1001/jamapediatrics.2020.3359

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Steven Selbst, MD
Earls and Flower
Cassidy Foley Davelaar, DO, FAAP, CAQSM
Breaking down toddler formulas and the confusion associated with naming, labeling | Image Credit: © University of Kentucky - © University of Kentucky - stock.adobe.com.
James Wallace, MD | Image Credit: Provided by James Wallace, MD
James Wallace, MD | Image Credit: Provided by James Wallace, MD
Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California | Image provided
Thomas R. Young, MD | Image Credit: Author provided
Related Content
© 2024 MJH Life Sciences

All rights reserved.